905P - Epigenetic signatures of RASSF1 and PTEN genes as potential candidates for targeting epithelial ovarian cancer

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Ovarian Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Mariyam Zuberi
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors M. Zuberi1, R. Mir1, I. Ahmad1, J. Javid1, P. Yadav1, S. Guru1, M. Masroor1, M. Bhat1, P.C. Ray1, G. Gandhi2, A. Saxena1
  • 1Biochemistry, Maulana Azad Medical College, 110002 - New Delhi/IN
  • 2Gynecology, Lok Nayak Hospital, 110002 - New Delhi/IN



Ovarian cancer is a fatal gynaecological cancer and a major cause of cancer-related mortality worldwide. Tumour suppressor genes (TSGs) are wild-type alleles of genes which play primary regulatory roles in diverse cellular activities, and whose loss of function contributes to the development of cancer. The present study aimed to investigate the methylation status in promoter region of RASSF1 gene and to study differential DNA methylation pattern of PTEN gene in Epithelial ovarian cancer patients in North India.


50 patients and 20 healthy controls were incorporated in the study. Isolation of genomic DNA from peripheral blood and methylation -specific PCR (MSP) were applied.


17 out of 50 patients (34.0%) were found to be methylated for RASSF1 gene, while methylation of the PTEN gene occurred in 8 of 50 cases (16.0%). A statistically significant result was obtained (p = 0.01) for RASSF1 gene that correlated with the patients clinico pathological features. However, no association could be established with the PTEN gene and the patients' clinical history.


Hypermethylation of RASSF1 gene in blood DNA from ovarian cancer patients might offer an exposition for early diagnosis of the malignancy. This study might be extrapolated further for possible epigenetic therapies targeting epigenetically dysregulated genes in ovarian cancer. A better understanding of the epigenetic changes in ovarian cancer will contribute to the improvement of patient outcomes.


All authors have declared no conflicts of interest.